Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Senticell Closes Oversubscribed Seed Round of $7M to Advance RBC-Based Liquid Biopsy Platform, Led by The Venture City and Others.
PRIVATESep 01, 2026•6 days ago
Amount Raised
$7 Million
Round Type
Seed
PhiladelphiaBiotechnologyHealth CareTherapeutics
Investors
Evoce CapitalScalpel VenturesCapital FactoryThe Venture City
Description
Senticell, Inc. has announced the closing of an oversubscribed seed financing round approaching $7 million. The funding will be utilized to run multiple clinical studies in oncology highlighting a novel red blood cell-based liquid biopsy platform. Investors include The Venture City, Capital Factory, Scalpel Ventures, and Evoce Capital
Company Information
Company
Senticell
Location
Philadelphia, Pennsylvania, United States
About
Senticell, Inc. is a biotechnology company pioneering a new class of liquid biopsy based on red blood cell (RBC)-bound nucleic acids. The company focuses on developing a novel platform for cancer diagnosis that aims to identify clinically actionable disease signals that traditional plasma-based tests may miss. With a foundation built on over a decade of research, Senticell's technology seeks to improve patient lives by transforming cancer detection. The platform is exclusively licensed from the University of Pennsylvania and is underpinned by significant scientific insights.
Don't miss Senticell's next move
Get an email the moment Senticell raises, hires an exec, or expands, usually minutes after it happens.
PhiladelphiaBiotechnologyHealth CareTherapeutics